1. Home
  2. PRTA vs IHRT Comparison

PRTA vs IHRT Comparison

Compare PRTA & IHRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$8.52

Market Cap

501.2M

Sector

Health Care

ML Signal

HOLD

Logo iHeartMedia Inc.

IHRT

iHeartMedia Inc.

HOLD

Current Price

$2.59

Market Cap

552.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRTA
IHRT
Founded
2012
1974
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Broadcasting
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
501.2M
552.6M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
PRTA
IHRT
Price
$8.52
$2.59
Analyst Decision
Buy
Hold
Analyst Count
9
3
Target Price
$19.00
$4.33
AVG Volume (30 Days)
467.7K
814.6K
Earning Date
05-07-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$814,000.00
N/A
Revenue This Year
$1,111.38
$7.45
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.32
$0.95
52 Week High
$13.71
$5.44

Technical Indicators

Market Signals
Indicator
PRTA
IHRT
Relative Strength Index (RSI) 38.64 33.49
Support Level $8.13 $1.95
Resistance Level $8.78 $2.63
Average True Range (ATR) 0.47 0.26
MACD -0.10 -0.03
Stochastic Oscillator 8.30 13.90

Price Performance

Historical Comparison
PRTA
IHRT

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

About IHRT iHeartMedia Inc.

iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.

Share on Social Networks: